NCT04286607

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

CompletedPHASE3INTERVENTIONAL

Trial Details

Start: 2020-02-12Est. Completion: 2024-01-22

Enrollment target: 337 participants

Locations

Arcutis Biotherapeutics Clinical Site 203, Scottsdale, Arizona, United States
Arcutis Biotherapeutics Clinical Site 239, Beverly Hills, California, United States
Arcutis Biotherapeutics Clinical Site 127, Encinitas, California, United States
Arcutis Biotherapeutics Clinical Site 225, Encino, California, United States
Arcutis Biotherapeutics Clinical Site 509, Fountain Valley, California, United States
Arcutis Biotherapeutics Clinical Site 112, Fremont, California, United States
Arcutis Biotherapeutics Clinical Site 120, Irvine, California, United States
Arcutis Biotherapeutics Clinical Site 508, Los Angeles, California, United States
Arcutis Biotherapeutics Clinical Site 511, Rancho Santa Margarita, California, United States
Arcutis Biotherapeutics Clinical Site 123, San Diego, California, United States
Arcutis Biotherapeutics Clinical Site 220, San Diego, California, United States
Arcutis Biotherapeutics Clinical Site 136, San Francisco, California, United States
Arcutis Biotherapeutics Clinical Site 208, Santa Monica, California, United States
Arcutis Biotherapeutics Clinical Site 215, Santa Monica, California, United States

Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasi…

Mesa, United StatesEst. completion May 18, 2027

Plaque Psoriasis

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white sca…

Calgary, CanadaEst. completion Mar 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.